We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
41.00 | 2.26% | 1,854.00 | 1,839.00 | 1,841.00 | 1,882.00 | 1,750.00 | 1,750.00 | 760,985 | 16:35:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.19 | 4.07B |
TIDMHIK
RNS Number : 3602O
Hikma Pharmaceuticals Plc
08 February 2021
London, February 8, 2021 - Hikma Pharmaceuticals PLC (Hikma), will announce its preliminary financial results for the year ended 31 December 2020 on Thursday 25 February 2021.
A recording of the presentation will be available on the Company's website at www.hikma.com from 8:00am GMT. Hikma will also hold a live Q&A conference call for analysts at 10:00am GMT, and a recording will be made available on the Company's website later that day.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal EVP, Strategic Planning and Global +44 (0)20 7399 2760/ +44 7776 Affairs 477050
Teneo
Charles Armitstead +44 (0)7703 330 269
Camilla Cunningham + 44 (0) 7464 982426
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORKZGGZDRDGMZM
(END) Dow Jones Newswires
February 08, 2021 09:55 ET (14:55 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions